Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alpha Tau Medical Ltd. - Ordinary Shares (NQ:DRTS)

3.790 -0.070 (-1.81%)
Streaming Delayed Price Updated: 11:22 AM EST, Nov 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,377
Open 3.890
Bid (Size) 3.800 (1,400)
Ask (Size) 3.830 (600)
Prev. Close 3.860
Today's Range 3.750 - 3.905
52wk Range 2.140 - 4.690
Shares Outstanding 68,575,397
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
From Alpha Tau Medical Ltd.
Via GlobeNewswire

Performance

YTD
+22.3%
+22.3%
1 Month
+0.3%
+0.3%
3 Month
+6.5%
+6.5%
6 Month
+35.4%
+35.4%
1 Year
+68.4%
+68.4%

More News

Read More
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Expert Ratings for Alpha Tau Medical
Via Benzinga
Alpha Tau Stock Rallies To 3-Month High On Smaller-Than-Feared Q1 Loss: Retail Sentiment Stays Bearish
Via Stocktwits
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Via ACCESS Newswire
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Treats First Patient with Recurrent Lung Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
From Alpha Tau Medical Ltd.
Via GlobeNewswire
DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q2 2024
Via InvestorPlace
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
From Alpha Tau Medical Ltd.
Via GlobeNewswire
DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q1 2024
Via InvestorPlace
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Alpha Tau Medical Ltd. - Ordinary Shares publicly traded?
Yes, Alpha Tau Medical Ltd. - Ordinary Shares is publicly traded.
What exchange does Alpha Tau Medical Ltd. - Ordinary Shares trade on?
Alpha Tau Medical Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Alpha Tau Medical Ltd. - Ordinary Shares?
The ticker symbol for Alpha Tau Medical Ltd. - Ordinary Shares is DRTS on the Nasdaq Stock Market
What is the current price of Alpha Tau Medical Ltd. - Ordinary Shares?
The current price of Alpha Tau Medical Ltd. - Ordinary Shares is 3.790
When was Alpha Tau Medical Ltd. - Ordinary Shares last traded?
The last trade of Alpha Tau Medical Ltd. - Ordinary Shares was at 11/10/25 11:22 AM ET
What is the market capitalization of Alpha Tau Medical Ltd. - Ordinary Shares?
The market capitalization of Alpha Tau Medical Ltd. - Ordinary Shares is 259.90M
How many shares of Alpha Tau Medical Ltd. - Ordinary Shares are outstanding?
Alpha Tau Medical Ltd. - Ordinary Shares has 260M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.